HCM
ANIK icon

Highbridge Capital Management’s Anika Therapeutics ANIK Stock Holding History

Highbridge Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-19,396
Closed -$843K – 1221
2017
Q1 		$843K Buy
+19,396
New +$926K 0.01% 677

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Highbridge Capital Management's ANIK Position: Q2 2017 in Review

Highbridge Capital Management sold out of Anika Therapeutics (ANIK) in Q2 2017, closing a stake of 19,396 shares — an estimated $843K sold.

Highbridge Capital Management first reported a position in ANIK in Q1 2017 and held it in 1 quarter. The position peaked at $843K in Q1 2017. 159 funds tracked by Wall St. Rank hold ANIK as of Q2 2017.

  • Highbridge Capital Management reported no remaining Anika Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 19,396 Anika Therapeutics shares in Q2 2017, an estimated $843K.
  • Highbridge Capital Management first reported a position in Anika Therapeutics in Q1 2017 and held it in 1 quarter.
  • Highbridge Capital Management's Anika Therapeutics position peaked at $843K in Q1 2017.
  • 159 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.